ES2027013T3 - Un procedimiento para preparar una forma de dosificacion de liberacion controlada. - Google Patents

Un procedimiento para preparar una forma de dosificacion de liberacion controlada.

Info

Publication number
ES2027013T3
ES2027013T3 ES198888310271T ES88310271T ES2027013T3 ES 2027013 T3 ES2027013 T3 ES 2027013T3 ES 198888310271 T ES198888310271 T ES 198888310271T ES 88310271 T ES88310271 T ES 88310271T ES 2027013 T3 ES2027013 T3 ES 2027013T3
Authority
ES
Spain
Prior art keywords
dosage form
controlled release
release dosage
medicinal product
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198888310271T
Other languages
English (en)
Inventor
Masayoshi Samejima
Kazuo Noda
Masao Kobayashi
Shigeyuki Ishikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Seiyaku Co Ltd
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Application granted granted Critical
Publication of ES2027013T3 publication Critical patent/ES2027013T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UNA FORMA DE DOSIFICACION DE LIBERACION CONTROLADA QUE CONSISTE ESENCIALMENTE EN UN NUCLEO QUE CONTIENE UN MEDICAMENTO, UN FORRO INTERIOR EN CAPAS COMPUESTO DE ETILCELULOSA Y UNA SUSTANCIA HIDROFOBICA, Y UN FORRO EXTERNO EN CAPAS QUE CONTIENE UN MEDICAMENTO SE DESCRIBE. DICHA FORMA DE DOSIFICACION MUESTRA UNA RAPIDA ELEVACION DE LA CONCETRACION EN SANGRE DEL MEDICAMENTO Y AL MISMO TIEMPO MANTIENE LOS ALTOS NIVELES EN LA CONCENTRACION SANGUINEA DURANTE UN PROLONGADO PERIODO DE TIEMPO.
ES198888310271T 1987-11-06 1988-11-01 Un procedimiento para preparar una forma de dosificacion de liberacion controlada. Expired - Lifetime ES2027013T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP28118987 1987-11-06

Publications (1)

Publication Number Publication Date
ES2027013T3 true ES2027013T3 (es) 1992-05-16

Family

ID=17635585

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198888310271T Expired - Lifetime ES2027013T3 (es) 1987-11-06 1988-11-01 Un procedimiento para preparar una forma de dosificacion de liberacion controlada.

Country Status (24)

Country Link
US (1) US4963365A (es)
EP (1) EP0315414B1 (es)
KR (1) KR940002655B1 (es)
CN (1) CN1035099C (es)
AT (1) ATE68343T1 (es)
AU (1) AU610275B2 (es)
BG (1) BG60638B1 (es)
CA (1) CA1331565C (es)
DE (1) DE3865631D1 (es)
DK (1) DK175249B1 (es)
ES (1) ES2027013T3 (es)
FI (1) FI96273C (es)
FR (1) FR2622799B1 (es)
GR (1) GR3002915T3 (es)
HK (1) HK44593A (es)
HU (1) HU201468B (es)
IE (1) IE60785B1 (es)
IL (1) IL88083A (es)
NO (1) NO176233C (es)
PH (1) PH25905A (es)
PT (1) PT88945B (es)
RU (1) RU1816213C (es)
SG (1) SG15493G (es)
ZA (1) ZA888147B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169642A (en) * 1988-06-24 1992-12-08 Abbott Laboratories Sustained-release drug dosage units
US5268182A (en) * 1988-06-24 1993-12-07 Abbott Laboratories Sustained-release drug dosage units of terazosin
ES2044246T3 (es) * 1989-02-11 1994-01-01 Bayer Ag Medicamentos con liberacion controlada del producto activo.
US5258186A (en) * 1989-03-10 1993-11-02 Yamanouchi Pharmaceutical Co., Ltd. Drug release controlling coating material for long acting formulations
WO1990011074A1 (en) * 1989-03-22 1990-10-04 Pang Peter K T Parathyroid hypertensive factor
US5886012A (en) * 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
JP2558396B2 (ja) * 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
DK0585355T3 (da) * 1991-05-20 1995-06-06 Tanabe Seiyaku Co Flerlagspræparat med reguleret frigivelse
ZA923474B (en) * 1991-05-20 1993-01-27 Marion Merrell Dow Inc Diltiazem formulation
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5252337A (en) * 1991-06-25 1993-10-12 Eurand America, Inc. Controlled release calcium channel blocker microcapsules
GB9117361D0 (en) * 1991-08-12 1991-09-25 Euro Celtique Sa Oral dosage form
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5492700A (en) * 1991-11-26 1996-02-20 Warner-Lambert Company Process and composition for the development of controlled release gemfibrozil dosage form
DE69327745T2 (de) * 1992-05-29 2000-09-21 Nikken Chemicals Co., Ltd. Tablette zur langsamen Freisetzung von Natriumvalproat
DE4342091A1 (de) * 1993-12-09 1995-06-14 Asta Medica Ag Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten
US5447729A (en) * 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5830503A (en) * 1996-06-21 1998-11-03 Andrx Pharmaceuticals, Inc. Enteric coated diltiazem once-a-day formulation
TW477708B (en) * 1996-09-13 2002-03-01 Shionogi & Amp Co Use of the thermal change to produce a substained release preparations and a process for their production
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
KR100396171B1 (ko) * 1998-08-10 2003-08-27 아사히 가세이 가부시키가이샤 염산 파수딜의 경구 서방성 제제
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
US6946146B2 (en) 2001-04-18 2005-09-20 Nostrum Pharmaceuticals Inc. Coating for a sustained release pharmaceutical composition
US20040029959A1 (en) * 2002-08-08 2004-02-12 John Devane Isosorbide mononitrate compositions and methods of their use
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
CA2529984C (en) 2003-06-26 2012-09-25 Isa Odidi Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
CN1296046C (zh) * 2003-12-23 2007-01-24 广州市医药工业研究所 盐酸地尔硫䓬控释胶囊剂及其制备方法
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
WO2007092717A1 (en) * 2006-02-07 2007-08-16 Fmc Corporation Latex or pseudolatex compositions coatings and coating processes
EP2007360B1 (en) 2006-04-03 2014-11-26 Isa Odidi Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US8927010B2 (en) * 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) * 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US10292937B2 (en) * 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
EP2529731A1 (en) * 2011-06-01 2012-12-05 Nitto Denko Corporation Particulate preparation and method for producing the same
FR2996418B1 (fr) * 2012-10-09 2015-05-29 Seppic Sa Compositions alimentaires comprenant des capsules obtenues par coacervation ne mettant pas en œuvre de reticulant toxique
WO2014078435A1 (en) 2012-11-14 2014-05-22 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1172087A (fr) * 1956-01-25 1959-02-05 Bellon Labor Sa Roger Perfectionnements concernant l'enrobage de préparations à effet retardé et à effet soutenu
US2921883A (en) * 1957-05-03 1960-01-19 Smith Kline French Lab Novel coating material for medicaments
US2928770A (en) * 1958-11-28 1960-03-15 Frank M Bardani Sustained action pill
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
IT1153487B (it) * 1982-04-15 1987-01-14 Prophin Lab Spa Prodotti farmaceutici in forma-ritardo e procedimento per ottenerli
US4390406A (en) * 1982-07-23 1983-06-28 Allied Corporation Replaceable outer junction double junction reference electrode
JPS604120A (ja) * 1983-06-22 1985-01-10 Shionogi & Co Ltd 作用持続型ピナシジル製剤
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
IT1206166B (it) * 1984-07-26 1989-04-14 Sigma Tau Ind Farmaceuti Dispositivo per rilasciare una sostanza in un fluido di dissoluzione con cinetica di ordine zero e procedimento per la sua preparazione
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
US4600645A (en) * 1985-01-31 1986-07-15 Warner-Lambert Company Process for treating dosage forms
JPS62103012A (ja) * 1985-10-23 1987-05-13 Eisai Co Ltd 多重顆粒
US4842867A (en) * 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
US4795644A (en) * 1987-08-03 1989-01-03 Merck & Co., Inc. Device for pH independent release of drugs through the Donnan-like influence of charged insoluble resins

Also Published As

Publication number Publication date
US4963365A (en) 1990-10-16
IE883246L (en) 1989-05-06
PH25905A (en) 1991-12-19
NO884947D0 (no) 1988-11-04
KR890007720A (ko) 1989-07-05
DK618088A (da) 1989-05-07
DK618088D0 (da) 1988-11-04
IL88083A (en) 1992-11-15
EP0315414A1 (en) 1989-05-10
AU610275B2 (en) 1991-05-16
IE60785B1 (en) 1994-08-10
HUT50624A (en) 1990-03-28
NO884947L (no) 1989-05-08
PT88945A (pt) 1989-11-30
FI96273B (fi) 1996-02-29
EP0315414B1 (en) 1991-10-16
FI885101A (fi) 1989-05-07
FR2622799A1 (fr) 1989-05-12
CN1035099C (zh) 1997-06-11
AU2472788A (en) 1989-05-11
SG15493G (en) 1993-04-16
PT88945B (pt) 1993-05-31
ATE68343T1 (de) 1991-11-15
DK175249B1 (da) 2004-07-19
FI885101A0 (fi) 1988-11-04
BG85941A (bg) 1993-12-24
GR3002915T3 (en) 1993-01-25
KR940002655B1 (ko) 1994-03-28
NO176233B (no) 1994-11-21
CN1033007A (zh) 1989-05-24
HK44593A (en) 1993-05-14
FI96273C (fi) 1996-06-10
HU201468B (en) 1990-11-28
FR2622799B1 (fr) 1991-11-29
BG60638B1 (bg) 1995-11-30
CA1331565C (en) 1994-08-23
IL88083A0 (en) 1989-06-30
NO176233C (no) 1995-03-01
RU1816213C (ru) 1993-05-15
ZA888147B (en) 1990-06-27
DE3865631D1 (de) 1991-11-21

Similar Documents

Publication Publication Date Title
ES2027013T3 (es) Un procedimiento para preparar una forma de dosificacion de liberacion controlada.
ES2053678T3 (es) Procedimiento para preparar un medicamento con contenido de azelastina para la aplicacion nasal y/u ocular.
ES2056832T5 (es) Vehiculo para la liberacion que contiene un agente activo asociado con una substancia anfifila.
ATE9695T1 (de) Antihistamine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE69000881D1 (de) 2-propylvaleriansaeure enthaltende arzneizubereitung mit verzoegerter wirkstofffreigabe.
IL59063A (en) Polymeric diffusion matrix for release of pharmaceutical dosage
NO157212C (no) Fremgangsmaate for fremstilling av belegg med lav emisjonsevne.
BE878883A (fr) Implant de delivrance de medicament pouvant etre enleve
GB2120937B (en) Implant for sustained release of pharmaceutical agents
NO163693C (no) Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser av platina.
JPS56156141A (en) Ultrasonic tomogram projection apparatus for body cavity
DE3370476D1 (en) Tetramethacrylic or tetraacrylic acid compounds and their use
MX7226E (es) Procedimiento para preparar una composicion insecticida que contiene piretroides y esteres tiofosforicos
NO830900L (no) Fremgangsmaate for fremstilling av terapeutisk aktive tricykliske derivater.
BR8009059A (pt) Administracao de substancia medicas ativas
IT8167585A0 (it) Composto chimico utilizzabile parti colarmente come agente farmaceutico antiulcera e procedimento per lasua fabbricazione
DE3068649D1 (en) Medicated device for controlled drug release
NO159590C (no) Analogifremgangsm te for fremstilling av terapeutisk aktive fenyleddiksyre-derivater.
ATA690679A (de) In den koerper implantierbare einrichtung zur konstanten abgabe eines wirkstoffs
NO160139C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive akridanonderivater.
NO153731C (no) Fremgangsmaate for isolering av fysiologisk aktive pterocarpanforbindelser i krystallinsk form.
EP0305194A3 (en) Veterinary composition
JPS55148562A (en) Liquid transport set for medical treatment
ZA815911B (en) Aminohydroxyphenyl compounds,processes for their manufacture,pharmaceutical preparations containing these compounds,and the use of these compounds
IT8053534V0 (it) Contenitore per bende ad uso farmaceutico

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 315414

Country of ref document: ES